美国血液透析患者高剂量流感疫苗接种情况(2010-2013)
基于美国肾脏数据系统2010-2013年421,482例成人血液透析患者的队列研究,比较了高剂量与标准三价流感疫苗的接种趋势及接种预测因素。任何流感疫苗接种比例从2010年的68.3%升至2013年的72.4%,但高剂量疫苗仅覆盖0.9%的患者,且16.7%的高剂量疫苗用于<65岁患者。高龄、医院附属透析机构与高剂量疫苗接种正相关,黑人及ESRD病程较长者接种可能性较低。
要点
- 血液透析患者任何流感疫苗接种率从2010年68.3%升至2013年72.4%。
- 研究期间仅0.9%患者接种高剂量疫苗,其中16.7%用于<65岁患者。
- ≥65岁患者中,>79岁较65-69岁更可能接种高剂量疫苗(OR 1.29)。
核心结论
- 尽管整体流感疫苗接种率有所上升,但ESRD患者高剂量疫苗使用率极低。
- 高龄、居住在中西部及在医院附属机构接受照护是高剂量疫苗接种的最强预测因素。
研究设计与样本
- 基于美国肾脏数据系统(2010-2013)的队列研究,纳入421,482例成人血液透析患者。
- 采用多变量逻辑回归评估个体层面变量(如 demographics、合并症)和机构层面变量(如机构规模和类型)与疫苗接种的关联。
主要发现
- 任何流感疫苗接种比例从2010年的68.3%增加至2013年的72.4%。
- 研究期间高剂量疫苗仅接种于0.9%的患者,且16.7%的高剂量疫苗 administered to patients <65 years of age。
- 在≥65岁患者中,>79岁较65-69岁更可能接种高剂量疫苗(OR 1.29;95%CI 1.19-1.41)。
- 在≥65岁患者中,医院附属透析机构较独立透析机构更可能接种高剂量疫苗(OR 2.31;95%CI 2.13-2.45)。
- 在≥65岁患者中,黑人较白人(OR 0.66;95%CI 0.61-0.71)及ESRD病程>9年较0年(OR 0.66;95%CI 0.55-0.78)更不可能接种高剂量疫苗。
临床怎么用
- 研究描述了美国血液透析患者高剂量流感疫苗的接种趋势及预测因素,未提供临床推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard influenza vaccines may be of limited benefit to patients with end-stage renal disease (ESRD). These patients may benefit from high-dose influenza vaccine, currently indicated for patients aged ≥65 years. Studies in other populations have demonstrated that high-dose vaccine elicits a stronger immunological response. We compared vaccine uptake in the United States and predictors of receipt for high-dose and standard influenza vaccines. METHODS: Using data from the United States Renal Data System (2010-2013), we conducted a cohort study of 421,482 adult patients on hemodialysis. We examined temporal trends in uptake of high-dose or standard trivalent influenza vaccine each influenza season, and used multivariate logistic regression to assess the association between individual-level variables (e.g., demographics, comorbidities) and facility-level variables (e.g., facility size and type) with vaccine receipt. RESULTS: The proportion of patients with ESRD who were vaccinated with any influenza vaccine increased from 68.3% in 2010 to 72.4% in 2013. High-dose vaccines were administered to 0.9% of patients during the study period, and 16.7% of high-dose vaccines were administered to patients <65 years of age. Among patients aged ≥65 years, older patients (>79 vs. 65-69 years: OR, 1.29; 95% CI, 1.19-1.41) and patients at hospital-based versus free-standing dialysis facilities (OR, 2.31; 95% CI, 2.13-2.45) were more likely to receive high-dose vaccine, while blacks (vs. whites [OR, 0.66; 95% CI, 0.61-0.71]) and patients with longer duration of ESRD (>9 vs. 0 years: OR, 0.66; 95% CI, 0.55-0.78) were less likely to receive the high-dose vaccine. CONCLUSIONS: While the overall influenza vaccination rate has increased, use of high-dose vaccine among patients with ESRD was very low. Being an older patient, living in the Midwest, and receiving care at hospital-based facilities were the strongest predictors of receiving high-dose vaccine.
引用
- McGrath LJ, Layton JB, Krueger WS, et al. High-dose influenza vaccine use among patients receiving hemodialysis in the United States, 2010-2013. Vaccine. 2018. PMID: 30195486. doi:10.1016/j.vaccine.2018.08.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。